Biogen Pursues Early-Stage Assets to Build Next Generation Growth Pipeline on April 30, 2026 Apellis acquisition assets Biogen early-stage growth strategy Immunology M&A Neurology speciality pipeline +
Biogen's Post-Apellis Strategy: Expanding Early-Stage Pipeline to Drive Next-Generation Growth on April 30, 2026 Apellis acquisition Biogen Drug Development Early-Stage Pipeline Immunology Nephrology Speciality Rare Diseases +
Biogen Acquires Apellis for $5.6 Billion to Expand Immunology and Kidney Disease Portfolio on March 31, 2026 Apellis acquisition Biogen Empaveli felzartamab Immunology Kidney Diseases Nephrology Speciality Syfovre +